DUBLIN–(BUSINESS WIRE)–The “Cytotoxic Drugs & HPAPI Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly Potent Finished Dosage Form and Key Geographies” report has been added to ResearchAndMarkets.com’s offering.
The global cytotoxic drugs and HPAPI manufacturing market is estimated to grow from USD 13.98 billion in the current year to USD 46.41 billion by 2035, at a CAGR of 12.75% during the forecast period, till 2035.
Cytotoxic Drugs and HPAPI Manufacturing Market: Growth and Trends
Due to the progress in clinical pharmacology and oncology, along with rising interest of players in targeted therapies, researchers and drug manufacturers worldwide are increasingly focusing on high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs. It is important to note that 45% of drugs worldwide are highly potent, necessitating the need for specialized production of HPAPIs. However, the manufacturing of HPAPIs involves a complicated process, leading to various challenges.
The primary challenge is preventing cross-contamination during production, followed by ensuring the safety of the environment and workers involved in the supply chain. Additionally, selecting the appropriate containment and protective measures, including equipment, procedures, and personal protective equipment (PPE), is crucial. Handling HPAPIs typically requires ongoing investment in safe handling practices, and advanced technical expertise, which further complicates the field. As a result, drug developers are increasingly turning to outsourcing their manufacturing processes.
Owing to the significant potential and favorable growth prospects of the contract manufacturing sector, most of the leading pharmaceutical companies are seeking to invest in the expansion or enhancement of their existing manufacturing facilities. Several contract manufacturing organizations (CMOs) are establishing new facilities in emerging markets such as Japan, China, India, and Brazil to benefit from lower production costs, skilled labor, and favorable regulatory environments in these regions. Driven by the overall expansion of the market, recent technological innovations, and a rising trend towards outsourcing, the sector is expected to experience consistent growth in the next decade.
Cytotoxic Drugs & HPAPI Manufacturing Market: Key Segments
HPAPI Segment Occupies the Largest Share of the Cytotoxic Drugs and HPAPI Manufacturing Market
Based on the type of product, the market is segmented into HPAPI and highly potent finished dosage forms. At present, HPAPI segment holds the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is unlikely to change in the near future.
Very Large Players are Likely to Dominate the Cytotoxic Drugs & HPAPI Manufacturing Market During the Forecast Period
Based on the company size, the market is segmented into small, mid-sized, large and very large companies. At present, very large companies hold the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is likely to remain the same in the coming decade.
By Scale of Operation, Commercial Scale is Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market
Based on scales of operation, the market is segmented into preclinical, clinical and commercial scales. It is worth highlighting that, at present, commercial scale holds a larger share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the forthcoming years.
Biologics is the Fastest Growing Segment of the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period
Based on the type of molecule, the market is segmented into small molecules and biologics. It is worth highlighting that, at present, small molecules dominate the cytotoxic drugs and HPAPI manufacturing market. This is primarily due to the fact the CMOs have invested and expanded their capabilities for highly potent small molecules. It is important to note the demand for highly potent drugs is on the rise, therefore the market for biologics is expected to grow at a faster pace in the coming decade.
Oral FDFs are Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period
Based on the type of highly potent finished dosage forms, the market is segmented into injectables, oral solids, creams and other FDFs. It is worth highlighting that, at present, oral FDFs capture the highest share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the coming decade owing to the benefits offered by oral formulations, such as cost-efficiency for manufacturers, comfort and ease of use for patients.
Europe Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority of the share is expected to be captured by players based in Europe. This is due to the fact that there are well-established players in this region with considerable installed capacities and capabilities. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.
Cytotoxic Drugs and HPAPI Manufacturing Market: Key Insights
- Presently, more than 140 players claim to have the required expertise to offer contract manufacturing services for highly potent compounds, across different scales of operation.
- The current market landscape is highly fragmented, featuring the presence of both new entrants and established players across key geographical regions.
- Leveraging their expertise, stakeholders are offering contract manufacturing services for a myriad of highly potent compounds; around 70% of the service providers possess analytical testing capability for HPAPIs.
- The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to HPAPI and cytotoxic drug manufacturing were inked in the recent past.
- In order to meet the rising demand for high potency compounds, CMOs have made elaborate investments to expand their facilities and capacities; this trend is most pronounced in the US, Switzerland and the UK.
- The installed global contract manufacturing capacity for HPAPIs is well distributed across different geographies; 80% of the present capacity is installed in facilities owned by very large players.
- Antibody Drug Conjugates are one of the most popular classes of highly potent compounds; more than 30 players currently claim to offer contract manufacturing / conjugation services for such biopharmaceuticals.
- It is anticipated that the highly potent drug developers are likely to outsource their manufacturing operations, enabling the service based revenues to grow at an annualized rate of 12.75%.
- The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders.
Cytotoxic Drugs and HPAPI Manufacturing Market: Research Coverage
- Market Sizing and Opportunity Analysis
- Market Landscape
- Company Competitiveness Analysis
- Company Profiles
- Partnerships and Collaborations
- Recent Expansions
- Capacity Analysis
- Regional Capability Assessment Analysis
- SWOT Analysis
- Case Study
Key Questions Answered in this Report
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Company Profiles
- AbbVie
- Cambrex
- Catalent
- Pfizer CentreOne
- Piramal Pharma Solutions
- Abzena
- Aenova
- CARBOGEN AMCIS
- Hovione
- Lonza
- Intas Pharmaceuticals
- Scinopharm
- STA Pharmaceutical (a WuXi AppTec company)
- Syngene
- Teva API
Report Scope
Type of Product
- HPAPIs
- Highly Potent Finished Dosage Forms
Scale of Operation
- Preclinical
- Clinical
- Commercial
Type of Molecule
- Small Molecules
- Biologics
Type of Highly Potent Finished Dosage Form
- Injectables
- Oral Solids
- Creams
- Others
Key Geographies
- North America (US, Canada and Mexico)
- Europe (UK, Italy, Germany, France, Spain, and Rest of Europe)
- Asia-Pacific (China, India, and Rest of Asia-Pacific)
- Rest of the World
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
For more information about this report visit https://www.researchandmarkets.com/r/seloat
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900